Chris Parker MD
Consultant in Clinical Oncology at the Royal Marsden Hospital and Honorary Senior Lecturer in Prostate Cancer Translational Research at the Institute of Cancer Research, Sutton, United KingdomDr. Chris Parker received an MB BChir degree from Merton College, Oxford, and subsequently an MRCP and FRCR. He earned an MD degree from the University of London.
Prior to his present appointment, he was a Clinical Research Fellow in the Department of Radiation Oncology at Princess Margaret Hospital in Toronto. Earlier, at St. Thomas’ Hospital in London, he served as Specialist Registrar in Clinical Oncology.
Since 2003, Dr. Parker has been a member of the Department of Health Prostate Cancer Advisory Group. For the past 2 years he has served with the NCRI Prostate Cancer Collaboratives Scientific Advisory Committee. Beginning in 2009, he chaired the MRC Trial Steering Committee for G-I and Gynae trials and has been a member of the Macmillan Cancer Support Clinical Advisory Board. He has been chairman of the RCR Clinical Oncology Research Committee since 2007.
Dr. Parker is currently a GU section editor for The Oncologist.
Positions:
Consultant in Clinical Oncology at the Royal Marsden Hospital
Senior Lecturer in Prostate Cancer Translational Research at the Institute of Cancer Research, Sutton
Degree:
University of London, MD
Postgraduate Training:
Clinical Research Fellow in the Department of Radiation Oncology, Princess Margaret Hospital, Toronto
Specialist Registrar in Clinical Oncology, St. Thomas’ Hospital, London
Research Fellow and Honorary Senior Registrar in Clinical Oncology, Institute of Cancer Research, Sutton
Clinical Interests:
Prostate Cancer Translational Research
Recent Contributions to PracticeUpdate:
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- Top Stories of 2012: Enzalutamide in Castration-Resistant Prostate Cancer
- Lean Body Mass Diminishes in Prostate Cancer Treated With ADT
- Intermittent Hormone Therapy Shortens Prostate Cancer Survival
- ERSSPC Follow-Up Affirms Benefit for PSA Screening
- PLCO Follow-Up Shows No Benefit For PSA Screening
- Seminal Articles-Prostate Cancer
- MDV3100 Cuts Risk of Death in Advanced Prostate Cancer
- Dr. Chris Parker: Radium-223 in Prostate Cancer Is a Landmark Finding